Clinical use of opioids for cancer pain

被引：6

作者：

Fitzgibbon D.R. ^{[1
]}

机构：

[1] Department of Anesthesiology, University of Washington School of Medicine, Seattle, WA 98195

来源：

Current Pain and Headache Reports | 2007年 / 11卷 / 4期

关键词：

Morphine; Cancer Pain; Oxycodone; Hydromorphone; Breakthrough Pain;

D O I：

10.1007/s11916-007-0200-x

中图分类号：

学科分类号：

摘要：

Successful management of pain in the cancer patient requires careful assessment of the components of the pain complaint and accurate diagnosis of the cause of pain. Symptomatic management of pain involves pharmacotherapeutic strategies that focus on opioid use. Factors influencing the choice of opioid in patients with cancer pain include the severity of pain, the presence of coexisting disease, response to previous analgesic therapy, pharmacokinetic factors, available formulations, and patient compliance. Long-term opioid prescription always requires individual titration of medication to adequate pain relief, which is determined on an individual patient basis and/or based on manageable adverse effects. Failure to continuously monitor opioid use generally results in overtreatment or undertreatment of pain. The cognitive and psychomotor effects of long-term opioid therapy are not well-defined and merit further study. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：251 / 258

页数：7

共 45 条

[1]

Practice guidelines for cancer pain management. A report by the American Society of Anesthesiologists Task Force on Pain Management, Cancer Pain Section, Anesthesiology, 84, pp. 1243-1257, (1996)

[2]

Bruera E., Kim H.N., Cancer pain, JAMA, 290, pp. 2476-2479, (2003)

[3]

Cancer Pain Relief with a Guide to Opioid Availability, (1996)

[4]

Resnik D.B., Rehm M., Minard R.B., The undertreatment of pain: Scientific, clinical, cultural, and philosophical factors, Med Health Care Philos, 4, pp. 277-288, (2001)

[5]

Elliott T.E., Murray D.M., Elliott B.A., Et al., Physician knowledge and attitudes about cancer pain management: A survey from the Minnesota cancer pain project, J Pain Symptom Manage, 10, pp. 494-504, (1995)

[6]

Joranson D.E., Gilson A.M., Dahl J.L., Haddox J.D., Pain management, controlled substances, and state medical board policy: A decade of change, J Pain Symptom Manage, 23, pp. 138-147, (2002)

[7]

Sloan P.A., Plymale M.A., Johnson M., Et al., Cancer pain management skills among medical students: The development of a Cancer Pain Objective Structured Clinical Examination, J Pain Symptom Manage, 21, pp. 298-306, (2001)

[8]

Fitzgibbon D.R., Galer B.S., The efficacy of opioids in cancer pain syndromes, Pain, 58, pp. 429-431, (1994)

[9]

Management of cancer pain guideline overview. Agency for Health Care Policy and Research. Rockville, Maryland, J Natl Med Assoc, 86, 571-573, (1994)

[10]

Zelman D.C., Smith M.Y., Hoffman D., Et al., Acceptable, manageable, and tolerable days: Patient daily goals for medication management of persistent pain, J Pain Symptom Manage, 28, pp. 474-487, (2004)

← 1 2 3 4 5 →